{"protocolSection":{"identificationModule":{"nctId":"NCT00149227","orgStudyIdInfo":{"id":"KHS2004"},"organization":{"fullName":"Kyoto Prefectural University of Medicine","class":"OTHER"},"briefTitle":"Add-on Effects of Valsartan on Morbi- Mortality (KYOTO HEART Study)","officialTitle":"Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension"},"statusModule":{"statusVerifiedDate":"2012-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2004-01"},"primaryCompletionDateStruct":{"date":"2009-01","type":"ACTUAL"},"completionDateStruct":{"date":"2009-01","type":"ACTUAL"},"studyFirstSubmitDate":"2005-09-06","studyFirstSubmitQcDate":"2005-09-06","studyFirstPostDateStruct":{"date":"2005-09-08","type":"ESTIMATED"},"resultsFirstSubmitDate":"2011-07-05","resultsFirstSubmitQcDate":"2012-12-09","resultsFirstPostDateStruct":{"date":"2012-12-12","type":"ESTIMATED"},"lastUpdateSubmitDate":"2012-12-09","lastUpdatePostDateStruct":{"date":"2012-12-12","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hiroaki Matsubara, MD., PhD","investigatorTitle":"Add-on Effects of Valsartan on Morbi- Mortality in High Risk Hypertension","investigatorAffiliation":"Kyoto Prefectural University of Medicine"},"leadSponsor":{"name":"Kyoto Prefectural University of Medicine","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients in Japan with hypertension in terms of the morbidity and mortality.","detailedDescription":"Although many reports show that ACE inhibitors and angiotensin II receptor blockers (ARB) are superior for prevention of cardiovascular events, previous data are not enough for the patients who have more than one risk factor and for anti-atherosclerotic effects of ARB. In Japan, there were only a few large-scale trials for cardiovascular disease prevention, and it has not been clarified whether the evidence in Western countries could be unqualifiedly applied to Japanese patients as a long-range strategy. The KYOTO HEART Study is to assess the add-on effect of valsartan, an Angiotensin-Receptor Blocker, on top of the conventional treatment in high risk patients with hypertension in terms of the morbidity and mortality."},"conditionsModule":{"conditions":["Hypertension","Ischemic Heart Disease","Congestive Heart Failure","Stroke"],"keywords":["High risk hypertension","Ischemic heart disease","Angiotensin receptor blockers","Cardiovascular mortality- morbidity","KYOTO HEART Study"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":3031,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Non-ARB","type":"ACTIVE_COMPARATOR","description":"'Non-ARB' was defined as Conventional anti-hypertensive treatment except for ARB and ACEIs","interventionNames":["Drug: Non-ARB"]},{"label":"Valsartan","type":"EXPERIMENTAL","description":"Valsartan add-on treatment","interventionNames":["Drug: Valsartan"]}],"interventions":[{"type":"DRUG","name":"Valsartan","description":"Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.","armGroupLabels":["Valsartan"],"otherNames":["Diovan"]},{"type":"DRUG","name":"Non-ARB","description":"'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs","armGroupLabels":["Non-ARB"],"otherNames":["Conventional anti-hypertensive treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"New Onset or Recurrence of Stroke","description":"Stroke events included brain hemorrhage, infarction, and TIA. They required hospitalization with neurological symptoms and were diagnosed by CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"New Onset or Recurrence of Transient Ischemic Attack","description":"Transient ischemic attack (TIA) was defined as hospitalization with sudden onset of neurological deficit persisting for less than 24 hrs, and without abnormal findings using by CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"New Onset or Recurrence of Acute Myocardial Infarction","description":"Acute myocardial infarction was diagnosed with hospitalization, ECG- change, and biomarkers for myocardial infarction. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"Hospitalization Due to the New Onset, Recurrence or Worsening of Heart Failure and Additional Concomitant Use of Other Anti-heart Failure Agents or Increase of Dosage","description":"Heart failure event was defined as requiring hospitalization and clinical symptoms together with left ventricular dysfunction by echocardiography according to the guidelines of the AHA/ACC. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"Hospitalization Due to the New Onset, Occurrence or Worsening of Angina Pectoris and Additional Concomitant Use of Other Anti-anginal Agents or Increase of Dosage","description":"Angina pectoris event required hospitalization and was diagnosed by both ECG changes corresponding with chest symptoms and coronary angiography showing 75% stenosis according to AHA/ACC guidelines. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"Operation of PCI or Bypass Operation","timeFrame":"five years"},{"measure":"New Onset of Acute Dissecting Aneurysm of the Aorta","description":"Dissecting aneurysm of the aorta required hospitalization and was diagnosed by imaging technique, CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"New Onset, Recurrence or Worsening of Arteriosclerosis Obliterans","description":"Arteriosclerosis obliterans (ASO) event was diagnosed with symptoms and CT / MRI imaging. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"Transition to Dialysis, Doubling of Plasma Cr Levels","description":"The first of any events, \"transition to dialysis\" or \"doubling of plasma Cr levels compared to the entry\", occurring in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"}],"secondaryOutcomes":[{"measure":"All Cause Mortality","timeFrame":"five years"},{"measure":"Worsening of Cardiac Function","timeFrame":"five years"},{"measure":"New Onset or Worsening of Arrhythmias","timeFrame":"five years"},{"measure":"New Onset or Worsening of Diabetes Mellitus or IGT","description":"Diabetes mellitus was defined as fasting plasma glucose \\>=126 mg/dl, causal blood glucose \\>= 200 mg /dl, HbA1C \\>= 6.5%, and/or plasma glucose 2hr after 75g glucose load \\>= 200 mg/dl. The first of these events, \"new onset diabetes\" or \"worsening diabetes following IGT\", occurring in a specific patient was classified as an event to be counted in the secondary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","timeFrame":"five years"},{"measure":"Uncontrolled Blood Pressure, Etc.","timeFrame":"five years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Clinical diagnosis of hypertension\n* Clinical diagnosis of one or more risk factors, such as diabetes, smoking habit, lipid metabolism abnormality, history of ischemic heart disease (IHD) or cerebrovascular disease, obesity (BMI\\>25), chronic heart failure (NYHA II-III), and electrocardiogram (ECG) abnormality (LVH)\n\nExclusion Criteria:\n\n* Patients who have already been administered ARB\n* Patients with IHD within 6 months after percutaneous coronary intervention(PCI), and who are stable but are going to implement PCI or coronary artery bypass grafting(CABG)\n* Severe/malignant/secondary hypertensive patients\n* Pregnant women and women of childbearing potential\n* History of heart failure, unstable angina, myocardial infarction, PTCA, or CABG within the preceding 6 months\n* Arrhythmia needed to be treated or accompanied with symptoms, second or third degree AV block\n* Severe renal impairment (Serum creatinine \\>3.0 mg/dl)\n* Severe hepatic impairment (Hepatic failure, Cirrhosis, etc.)","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"79 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Hiroaki Matsubara, MD,PhD","affiliation":"Kyoto Prefectural University of Medicine","role":"STUDY_CHAIR"}],"locations":[{"facility":"Kyoto Prefectural University of Medicine","city":"Kyoto","zip":"602-8566","country":"Japan","geoPoint":{"lat":35.02107,"lon":135.75385}}]},"referencesModule":{"references":[{"pmid":"18800142","type":"BACKGROUND","citation":"Sawada T, Takahashi T, Yamada H, Dahlof B, Matsubara H; KYOTO HEART Study Group. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events. J Hum Hypertens. 2009 Mar;23(3):188-95. doi: 10.1038/jhh.2008.116. Epub 2008 Sep 18. Erratum In: J Hum Hypertens. 2013 Sep;27(9):580."},{"pmid":"19723695","type":"RESULT","citation":"Sawada T, Yamada H, Dahlof B, Matsubara H; KYOTO HEART Study Group. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009 Oct;30(20):2461-9. doi: 10.1093/eurheartj/ehp363. Epub 2009 Aug 31.","retractions":[{"pmid":"23376450","source":"Eur Heart J. 2013 Apr;34(14):1023"}]}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Among 3042 patients eligible, 4 patients were withdrawn due to refusal of informed consent, 7 were withdrawn due to incompatible object. Finally, 3031 patients were assigned to the treatment groups.","recruitmentDetails":"We recruited patients between January 2004 and June 2007. Participating centres included 31 associated hospitals led by physicians (cardiology specialists) from Kyoto Prefectural University School of Medicine.","groups":[{"id":"FG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"FG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1517"},{"groupId":"FG001","numSubjects":"1514"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1517"},{"groupId":"FG001","numSubjects":"1514"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"BG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1517"},{"groupId":"BG001","value":"1514"},{"groupId":"BG002","value":"3031"}]}],"measures":[{"title":"Age Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"65.8","spread":"11.2"},{"groupId":"BG001","value":"66.1","spread":"10.9"},{"groupId":"BG002","value":"65.9","spread":"11.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"656"},{"groupId":"BG001","value":"647"},{"groupId":"BG002","value":"1303"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"861"},{"groupId":"BG001","value":"867"},{"groupId":"BG002","value":"1728"}]}]}]},{"title":"Region of Enrollment","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Japan","categories":[{"measurements":[{"groupId":"BG000","value":"1517"},{"groupId":"BG001","value":"1514"},{"groupId":"BG002","value":"3031"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"New Onset or Recurrence of Stroke","description":"Stroke events included brain hemorrhage, infarction, and TIA. They required hospitalization with neurological symptoms and were diagnosed by CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","populationDescription":"Analyses were made by the independent Statistical Analysis Organization based on the intention-to-treat principle.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"46"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.\n\nwith a two-tailed 5% statistical signiﬁcant level.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.05","statisticalMethod":"Cox's proportional hazard analysis","paramType":"Cox Proportional Hazard","paramValue":"0.8","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.975","ciUpperLimit":"0.975","dispersionType":"STANDARD_DEVIATION","dispersionValue":"2"}]},{"type":"PRIMARY","title":"New Onset or Recurrence of Transient Ischemic Attack","description":"Transient ischemic attack (TIA) was defined as hospitalization with sudden onset of neurological deficit persisting for less than 24 hrs, and without abnormal findings using by CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"}]}]}]},{"type":"PRIMARY","title":"New Onset or Recurrence of Acute Myocardial Infarction","description":"Acute myocardial infarction was diagnosed with hospitalization, ECG- change, and biomarkers for myocardial infarction. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}]}]}]},{"type":"PRIMARY","title":"Hospitalization Due to the New Onset, Recurrence or Worsening of Heart Failure and Additional Concomitant Use of Other Anti-heart Failure Agents or Increase of Dosage","description":"Heart failure event was defined as requiring hospitalization and clinical symptoms together with left ventricular dysfunction by echocardiography according to the guidelines of the AHA/ACC. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"26"}]}]}]},{"type":"PRIMARY","title":"Hospitalization Due to the New Onset, Occurrence or Worsening of Angina Pectoris and Additional Concomitant Use of Other Anti-anginal Agents or Increase of Dosage","description":"Angina pectoris event required hospitalization and was diagnosed by both ECG changes corresponding with chest symptoms and coronary angiography showing 75% stenosis according to AHA/ACC guidelines. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"44"}]}]}]},{"type":"PRIMARY","title":"Operation of PCI or Bypass Operation","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years"},{"type":"PRIMARY","title":"New Onset of Acute Dissecting Aneurysm of the Aorta","description":"Dissecting aneurysm of the aorta required hospitalization and was diagnosed by imaging technique, CT and/or MRI. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"}]}]}]},{"type":"PRIMARY","title":"New Onset, Recurrence or Worsening of Arteriosclerosis Obliterans","description":"Arteriosclerosis obliterans (ASO) event was diagnosed with symptoms and CT / MRI imaging. The first of any of these events to occur in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"}]}]}]},{"type":"PRIMARY","title":"Transition to Dialysis, Doubling of Plasma Cr Levels","description":"The first of any events, \"transition to dialysis\" or \"doubling of plasma Cr levels compared to the entry\", occurring in a specific patient was classified as an event to be counted in the primary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"14"}]}]}]},{"type":"SECONDARY","title":"All Cause Mortality","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"32"}]}]}]},{"type":"SECONDARY","title":"Worsening of Cardiac Function","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years"},{"type":"SECONDARY","title":"New Onset or Worsening of Arrhythmias","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years"},{"type":"SECONDARY","title":"New Onset or Worsening of Diabetes Mellitus or IGT","description":"Diabetes mellitus was defined as fasting plasma glucose \\>=126 mg/dl, causal blood glucose \\>= 200 mg /dl, HbA1C \\>= 6.5%, and/or plasma glucose 2hr after 75g glucose load \\>= 200 mg/dl. The first of these events, \"new onset diabetes\" or \"worsening diabetes following IGT\", occurring in a specific patient was classified as an event to be counted in the secondary endpoint by the Endpoint Committee. We estimated the number of enrolled patients to validate the hypothesis under the assumption that the valsartan add-on group achieves a 20% risk reduction compared with the conventional treatment group and gives 80% statistical power for detecting a clinical signiﬁcance with a two-tailed 5% statistical signiﬁcant level.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"event number","timeFrame":"five years","groups":[{"id":"OG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary."},{"id":"OG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1517"},{"groupId":"OG001","value":"1514"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"86"}]}]}]},{"type":"SECONDARY","title":"Uncontrolled Blood Pressure, Etc.","reportingStatus":"NOT_POSTED","paramType":"NUMBER","unitOfMeasure":"patients","timeFrame":"five years"}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Valsartan","description":"For the valsartan add-on group, valsartan 80 mg once daily in the morning was administered to the patient as an initial dose, the dose was doubled after 4 weeks if the initial dose could not achieve the target blood pressure of less than 140/90 mmHg (in patients with diabetes or renal disease, target blood pressure was set to less than 130/80 mmHg). After 8 weeks, an additional administration of other antihypertensive drugs with ﬂexible dosing regimen other than ARBs and ACE inhibitors was allowed if necessary.","seriousNumAffected":0,"seriousNumAtRisk":1517,"otherNumAffected":0,"otherNumAtRisk":1517},{"id":"EG001","title":"Non-ARB","description":"For the conventional treatment group, the anti-hypertensive drugs other than ARB and ACE inhibitors were provided for the patients to reach the target blood pressure.","seriousNumAffected":0,"seriousNumAtRisk":1514,"otherNumAffected":0,"otherNumAtRisk":1514}]},"moreInfoModule":{"limitationsAndCaveats":{"description":"The study was performed using PROBE design, which does not exclude possible bias for softer endpoints such as angina and TIA. However, all softer endpoints were diagnosed by CAG and CT/MRI. We believe that under reporting would be unlikely."},"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Prof. Hiroaki Matsubara","organization":"Department of Cardiology, Kyoto Prefectural University of Medicine","email":"matsubah@koto.kpu-m.ac.jp","phone":"+81-75-251-5511"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000006973","term":"Hypertension"},{"id":"D000006333","term":"Heart Failure"},{"id":"D000006331","term":"Heart Diseases"},{"id":"D000017202","term":"Myocardial Ischemia"},{"id":"D000003324","term":"Coronary Artery Disease"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000003327","term":"Coronary Disease"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9111","name":"Heart Failure","asFound":"Congestive Heart Failure","relevance":"HIGH"},{"id":"M9714","name":"Hypertension","asFound":"Hypertension","relevance":"HIGH"},{"id":"M6236","name":"Coronary Artery Disease","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M19196","name":"Myocardial Ischemia","asFound":"Ischemic Heart Disease","relevance":"HIGH"},{"id":"M9109","name":"Heart Diseases","asFound":"Heart Disease","relevance":"HIGH"},{"id":"M6239","name":"Coronary Disease","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000068756","term":"Valsartan"},{"id":"D000000959","term":"Antihypertensive Agents"}],"ancestors":[{"id":"D000047228","term":"Angiotensin II Type 1 Receptor Blockers"},{"id":"D000057911","term":"Angiotensin Receptor Antagonists"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M301","name":"Valsartan","asFound":"Mechanical","relevance":"HIGH"},{"id":"M3967","name":"Antihypertensive Agents","asFound":"Study personnel","relevance":"HIGH"},{"id":"M28606","name":"Angiotensin Receptor Antagonists","relevance":"LOW"},{"id":"M3824","name":"Angiotensin-Converting Enzyme Inhibitors","relevance":"LOW"},{"id":"M3822","name":"Angiotensin II","relevance":"LOW"},{"id":"M289298","name":"Giapreza","relevance":"LOW"},{"id":"M3825","name":"Angiotensinogen","relevance":"LOW"},{"id":"M25479","name":"Angiotensin II Type 1 Receptor Blockers","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnAg","name":"Antihypertensive Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaCoAg","name":"Vasoconstrictor Agents"}]}},"hasResults":true}